CYAD Celyad SA

11.1
-0.16  -1%
Previous Close 11.26
Open 11.6
Price To Book 3.39
Market Cap 154,760,018
Shares 13,942,344
Volume 18,253
Short Ratio
Av. Daily Volume 50,877
Stock charts supplied by TradingView

NewsSee all news

  1. Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

    Preliminary data from the Phase 1 CYCLE-1 trial are expected during second half 2020 MONT-SAINT-GUIBERT, Belgium, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage

  2. Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

    Future development of relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) program to be underpinned by proprietary OptimAb manufacturing processEnrollment of DEPLETHINK trial

  3. Celyad Receives Additional €2.5 Million in Non-Dilutive Funding

    MONT-SAINT-GUIBERT, Belgium, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today

  4. Celyad Announces Board of Directors Evolution with New Appointment

    Dr. Christian Homsy steps down from the Celyad Board of Directors as current CEO Filippo Petti is nominated into the role MONT-SAINT-GUIBERT, Belgium, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and

  5. Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

    Funding will support the advancement of the Company's autologous and allogeneic CAR-T cell therapy programs  MONT-SAINT-GUIBERT, Belgium, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data did not meet primary endpoint
C-Cure - Chart 1 trial
Chronic Heart Failure secondary to ischemic cardiomyopathy
Phase 1 expansion data due 1H 2020.
CYAD-01 - THINK
Various cancers - solid and hematologic cancers
Phase 1 further data due 1H 2020.
CYAD-101 - alloSHRINK
Colorectal cancer
Phase 1 data presented at SITC November 8, 2019.
CYAD-01 and FOLFOX - SHRINK
Colorectal cancer
Phase 1 data from cohorts 3 and 4 due 1H 2020.
CYAD-01 and chemotherapy (DEPLETHINK)
AML or myelodysplastic syndrome (MDS)
Phase 1 initiation of dosing announced January 13, 2020 with data due 2H 2020.
CYAD-02 CYCLE-1
Relapsed/refractory Acute myeloid leukemia (AML) and Myelodysplastic Syndrome (MDS)

Latest News

  1. Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

    Preliminary data from the Phase 1 CYCLE-1 trial are expected during second half 2020 MONT-SAINT-GUIBERT, Belgium, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage

  2. Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

    Future development of relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) program to be underpinned by proprietary OptimAb manufacturing processEnrollment of DEPLETHINK trial

  3. Celyad Receives Additional €2.5 Million in Non-Dilutive Funding

    MONT-SAINT-GUIBERT, Belgium, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today

  4. Celyad Announces Board of Directors Evolution with New Appointment

    Dr. Christian Homsy steps down from the Celyad Board of Directors as current CEO Filippo Petti is nominated into the role MONT-SAINT-GUIBERT, Belgium, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and

  5. Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

    Funding will support the advancement of the Company's autologous and allogeneic CAR-T cell therapy programs  MONT-SAINT-GUIBERT, Belgium, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris,

  6. Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights

    MONT-SAINT-GUIBERT, Belgium, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today

  7. Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

    Results from ongoing, dose-escalation alloSHRINK Phase 1 trial demonstrate absence of graft-versus-host disease for first-in-class, non-gene edited allogeneic CAR-T candidate, CYAD-101, when administered concurrently

  8. Celyad Highlights Abstracts from mCRC Clinical Program Released for SITC 34th Annual Meeting

    Management to host webcast on Saturday, Nov. 9, at 12:35 p.m. ET/ 6:35 p.m. CET MONT-SAINT-GUIBERT, Belgium, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage

  9. Celyad Announces October and November 2019 Investor Conference Schedule

    MONT-SAINT-GUIBERT, Belgium, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies,

  10. Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting

    Poster presentations to highlight allogeneic and autologous NKG2D-based CAR-T therapies for the treatment of advanced metastatic colorectal (mCRC) cancers MONT-SAINT-GUIBERT, Belgium, Oct. 02, 2019 (GLOBE NEWSWIRE) --

  11. Celyad Announces Closing of $20 Million Global Offering

    MONT-SAINT-GUIBERT, Belgium, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today

  12. Horizon Discovery Group plc: Results for the Six Months Ended 30 June 2019

    RNS Horizon Discovery Group plcResults for the Six Months Ended 30 June 2019 Cambridge, UK, 16 September 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or "the Company"), a global

  13. Celyad Announces Pricing of $20.0 Million Global Offering

    MONT-SAINT-GUIBERT, Belgium, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today

  14. Celyad Announces Launch of Proposed Global Offering

    MONT-SAINT-GUIBERT, Belgium, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies,

  15. Be The Match BioTherapies® and Celyad Announce Collaboration to Advance Development of Allogeneic CAR-T Therapies

    Alliance will support the clinical progression of Celyad's non-gene edited allogeneic CAR-T candidates Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell

  16. Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process

    MONT-SAINT-GUIBERT, Belgium, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies,

  17. Celyad to Participate in Upcoming September 2019 Conferences

    MONT-SAINT-GUIBERT, Belgium, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies,

  18. Celyad Reports Half Year 2019 Financial Results and Second Quarter Business Highlights

    MONT-SAINT-GUIBERT, Belgium, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today